1. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements
reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci
1999;44:1317-21. 2. Oelgoetz AW, Oelgoetz PA, Wittenkind J. The treatment of food allergy
and indigestion of pancreatic origin with pancreatic enzymes. Am J Dig Dis Nutr
1935;2:422-6. 3. McCann M. Pancreatic enzyme supplement for treatment of multiple food
allergies. Ann Allergy 1993;71:269 [abstr #17]. 4. Ambrus JL, Lassman HB, DeMarchi JJ. Absorption of exogenous and
endogenous proteolytic enzymes. Clin Pharmacol Ther 1967;8:362-8. 5. Avakian S. Further studies on the absorption of chymotrypsin. Clin
Pharmacol Ther 1964;5:712-5. 6. Izaka K, Yamada M, Kawano T, Suyama T. Gastrointestinal absorption and
anti-inflammatory effect of bromelain. Jpn J Pharmacol 1972;22:519-34. 7. Deitrick RE. Oral proteolytic enzymes in the treatment of athletic
injuries: a double-blind study. Pennsylvania Med J 1965;Oct:35-7. 8. Seligman B. Bromelain: an anti-inflammatory agent. Angiology
1962;13:508-10. 9. Cichoke AJ. The effect of systemic enzyme therapy on cancer cells and
the immune system. Townsend Letter for Doctors and Patients 1995;Nov:30-2
[review]. 10. Wolf M, Ransberger K. Enzyme Therapy. New York: Vantage
Press 1972, 135-220 [review]. 11. Gonzalez NJ, Isaacs, LL. Evaluation of pancreatic proteolytic enzyme
treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support.
Nutr Cancer 1999;33:117-24. 12. Kleine MW, Stauder GM, Beese EW. The intestinal absorption of orally
administered hydrolytic enzymes and their effects in the treatment of acute herpes zoster as
compared with those of oral acyclovir therapy. Phytomedicine 1995;2:7-15. 13. Patel RS, Johlin FC Jr, Murray JA. Celiac disease and recurrent
pancreatitis. Gastrointest Endosc 1999;50:823–7. 14. Gullo L. Indication for pancreatic enzyme treatment in non-pancreatic
digestive diseases. Digestion 1993;54(suppl 2):43–7. 15. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements
reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci
1999;44:1317–21. 16. Nakamura T, Tandoh Y, Terada A, et al. Effects of high-lipase
pancreatin on fecal fat, neutral sterol, bile acid, and short-chain fatty acid excretion in
patients with pancreatic insufficiency resulting from chronic pancreatitis. Int J
Pancreatol 1998;23:63–70. 17. Taylor CJ, Hillel PG, Ghosal S, et al. Gastric emptying and
intestinal transit of pancreatic enzyme supplements in cystic fibrosis. Arch Dis
Child 1999;80:149–52. 18. Layer P, Groger G. Fate of pancreatic enzymes in the human intestinal
lumen in health and pancreatic insufficiency. Digestion 1993;54(suppl
2):10–4. 19. Stevens JC, Maguiness KM, Hollingsworth J, et al. Pancreatic enzyme
supplementation in cystic fibrosis patients before and after fibrosing colonopathy. J
Pediatr Gastroenterol Nutr 1998;26:80–4. 20. Oades PJ, Bush A, Ong PS, Brereton RJ. High-strength pancreatic
enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994;343:109
[letter]. 21. Campbell CA, Forrest J, Muscgrove C. High-strength pancreatic enzyme
supplements and large-bowel stricture in cystic fibrosis. Lancet
1994;343:109–10 [letter]. 22. Milla CE, Wielinski CL, Warwick WJ. High-strength pancreatic enzymes.
Lancet 1994;343:599 [letter]. 23. Jones R, Franklin K, Spicer R, Berry J. Colonic strictures in
children with cystic fibrosis on low-strength pancreatic enzymes. Lancet
1995;346:499–500 [letter]. 24. Powell CJ. Pancreatic enzymes and fibrosing colonopathy.
Lancet 1999;354:251 [letter]. |